Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Pericardial effusion in COVID-19 patients

Dear Editor:

Pericardial effusion is a well-known complication of several viral infections, such as Influenza virus, Coxsackievirus, and Echovirus. Apart from case reports and small retrospective observational studies, little is known about the incidence of COVID-19-related pericardial effusion. In patients without preexisting cardiac disease, COVID-19 has been shown to cause congestive heart failure, myocarditis, Takotsubo cardiomyopathy, and myocardial infarction through direct and indirect effect on the myocytes. Several hypotheses exist suggesting that COVID-19-induced pericardial effusion is a result of a severe inflammatory process than direct infectious cause.

This study was a retrospective review of all adult COVID-19 patients admitted to Albany Medical Center (AMC) in Albany, New York, between the dates of March 1st, 2020 to January 10th, 2021. This study was approved by the AMC Institutional Review Board under number IRB protocol of #5825. Patients were diagnosed via real-time reverse transcription-polymerase chain reaction (RT-PCR) from a nasopharyngeal swab. COVID-19 patients who had an echocardiography performed as part of their standard medical care during hospitalization and found to have pericardial effusions were included in this case series. The most common indications for ordering echocardiography were identifying superimposed cardiogenic pulmonary edema in patients with COVID-19 related ARDS and assessing Bi-Ventricular function in patients with undifferentiated shock. The following data were collected for each patient in the study: (a) Demographics of age, sex, and ethnicity; (b) Comorbidities of coronary arterial disease, chronic pulmonary disease, diabetes mellitus, hypertension, and cancer; (c) Admission laboratory parameters of procalcitonin, ferritin, C-reactive protein (CRP), and D-dimer levels; (d) COVID-19 treatment such as Remdesivir, therapeutic anti-coagulation, corticosteroids, and convalescent plasma; (e) echocardiography findings of right ventricular size, function, right ventricular systolic pressure, left ventricular ejection fraction, pericardial effusion size, and pericardiocentesis requirement; and (f) Outcomes of in-hospital mortality, 28-day ventilator-free days, 28-day ICU-free days and 28-day hospital-free days.

A total of 1002 patients with COVID-19 infection were admitted to AMC during the study period. Echocardiography was performed on 195 of these, of which 4.6% (9/195) had evidence of pericardial effusions. The baseline clinical characteristics of COVID-19 patients with pericardial effusions are shown in Table 1. The mean/median age of patients were 60 and 66 years, respectively, and 33% (3/9) of the patients were male. The most common comorbidity was hypertension in 67% (6/9) of cases, followed by coronary artery disease at 44% (4/9), one patient had a past medical history of End Stage Kidney Disease 11% (1/9), and none had personal history of rheumatological diseases or evidence of bacteremia during their hospitalization. More than half of the patients received high-dose corticosteroids [55% (5/9)], but only 22.2% (2/9) received Remdesivir. 88.9% (8/9) of pericardial effusions identified on echocardiogram were small and the remaining one was moderate in size. None of these pericardial effusion patients required pericardiocentesis or fluid analysis were performed, and one patient had evidence of pericarditis on her electrocardiogram (EKG). 22.2% (2/9) of the patients had follow-up echocardiogram with persistent pericardial effusions identified. One-third (3/9) of the patients required ICU admission, of which two were mechanically ventilated. Finally, one-third (3/9) of the pericardial effusion patients died during their hospitalization. Other clinical outcomes are demonstrated in Table 2.

TABLE 1. Baseline demographics of COVID 19 patients with pericardial effusion.

| Variables                              | Patients with Pericardial Effusion N = 9 |
|----------------------------------------|-----------------------------------------|
| Age-Year; Mean (SD)                    | 66 (15.8)                               |
| Sex- N (%)                             |                                        |
| Male                                   | 3 (33.3%)                               |
| Female                                 | 6 (66.7%)                               |
| Ethnicities- N (%)                     |                                        |
| White                                  | 6 (66.7%)                               |
| Black                                  | 2 (22.2%)                               |
| Unknown/Not Reported                   | 1 (11.1%)                               |
| BMI Mean (SD)                          | 29.5 (9.6)                              |
| Comorbidities- N (%)                   |                                        |
| One Comorbidity                        | 7 (77.7%)                               |
| Chronic Pulmonary Disease              | 5 (55.5%)                               |
| Diabetes Mellitus                      | 2 (22.2%)                               |
| Coronary Artery Disease                | 4 (44.4%)                               |
| Hypertension                           | 6 (66.7%)                               |
| Cancer                                 | 0 (0%)                                  |
| Inflammatory markers Mean (SD)         |                                        |
| Procalcitonin (ng/mL)                  | 5 (12.7)                                |
| Ferritin (ng/mL)                       | 183.5 (181.3)                           |
| C-RP (mg/L)                            | 50 (57.6)                               |
| D-Dimer (ng/mL)                        | 4 (7.2)                                 |
| Treatment- N (%)                       |                                        |
| Corticosteroid                         | 5 (55.5%)                               |
| Convalescent Plasma                    | 4 (44.4%)                               |
| Therapeutic Anti-Coagulation           | 2 (22.2%)                               |
| Remdesivir                             | 2 (22.2%)                               |
TABLE 2. Association between presence of pericardial effusion and clinical outcome.

| Outcome                                | Patients with Pericardial Effusion   |
|-----------------------------------------|--------------------------------------|
| Mortality N (%)                         | N = 9                                |
| Number of days on ventilator; Mean, SD  | 9, 9                                 |
| (N = 3)                                 |                                      |
| Number of ICU Days; Mean, SD (N = 3)    | 10, 6.5                              |
| Hospital Length of Stay; Mean, SD       | 20, 14.1                             |
| 28 Ventilator free days; Mean, SD (N = 3)| 6.5, 9.1                             |
| 28 ICU free days; Mean, SD (N = 3)      | 3.6, 6.4                             |
| 28 Hospital free days; Mean, SD         | 6, 9.1                               |

Among 195 COVID-19 patients admitted to our tertiary care center who received echocardiography, the incidence of unprompted pericardial effusion was up to 4.6%. Our cohort data suggest that the presence of pericardial effusion in patients requiring mechanical ventilation led to extended ventilation times along with extended hospital stay. These patients subsequently had fewer ICU and ventilator free days.

Several case reports have discussed the incidence of pericardial effusion in COVID-19 patients. A prospective study found pericardial effusion in exceptionally 22% of COVID-19 patients more than two weeks after testing positive on RT-PCR. An observational study assessing the radiologic findings of COVID-19 patients also described an increased incidence of pericardial effusion.

It remains unclear if the occurrence of pericardial effusion in COVID-19 patients is related to underlying myocarditis or pericarditis. An observational study reported the incidence of myocarditis to be as high as 7% among 150 COVID-19 patients. Prior reports have correlated an incidence of pericardial effusion in patients with elevated cardiac troponin from less than 1% to as high as 10% in patients diagnosed with myocarditis. In much of the literature published on echocardiographic characteristics in COVID-19 patients, the focus was to demonstrate dynamics of ventricular action in diagnosis of myocarditis. Nevertheless, the true incidence of pericarditis in the setting of myopericarditis is not clear due to the limit on healthcare worker to patient exposure causing a reduction in the use of echocardiogram and avoidance of aerosolized-generating procedure, such as pericardial drainage of pericardial effusion. Furthermore, results of RT-PCR testing of pericardial effusion after pericardiocentesis have returned negative, casting doubts on SAR-CoV-2 testing of pericardial effusion after pericardiocentesis.

In conclusion, the incidence of COVID-19-related pericardial effusions appears to be low at 4.6% in our sample of COVID-19 patients. Other causative factors should be ruled out in COVID-19 patients diagnosed with pericardial effusions. Prior medical history may also play a key factor in presence of pericardial effusions in any patient examined with echocardiography. Further well-designed, large prospective studies are needed to determine the true incidence of pericardial effusions in COVID-19 patients.

Al-Hani Al-Tarbsheh, MD1,*
Annie Leamon, BS1
Woon H. Chong, MD2
Jae Keun Chung, DO1
Jozef Oweis, MBBS1
Srinivasan Vamshe, BS1
Om Dawani, MD2
Amit Chopra, MD2

1Department of Medicine, Albany Medical Center, Albany, NY, USA
2Division of Pulmonary and Critical Care Medicine, Department of Medicine, Albany Medical Center, Albany, NY, USA
*E-mail: altarba@amc.edu

REFERENCES
1. Gupta A, Madhavan MV, Sehgal K, et al. Extrapolmonary manifestations of COVID-19. Nat Med. 2020;26(7):1017–1032.
2. Dweck MR, Bularga A, Hahn RT, et al. Global evaluation of echocardiography in patients with COVID-19. Eur Heart J Cardiovasc Imaging. 2020;21(9):949–956.
3. Allam HH, Kinsara AJ, Tuaima T, Alfakih S. Pericardial fluid in a COVID-19 patient: Is it exudate or transudate? Eur J Case Rep Intern Med. 2020;7(6):001703.-001703.
4. Punthmann VO, Carej ML, Wieters I, et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19). JACC Cardiovasc Med. 2020;5(11):1265–1273.
5. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19: an analysis of data from 150 patients from Wuhan, China. Intensive Care Med. 2020;46(5):846–848.
6. Knight DS, Kotecha T, Razvi Y, et al. COVID-19: myocardial injury in survivors. Circulation. 2020;142(11):1120–1122.
7. Purohit R, Kanwal A, Pandit A, et al. Acute myopericarditis with pericardial effusion and cardiac tamponade in a patient with COVID-19. Am J Case Rep. 2020;21; e925554.
8. Mahmoud-Elsayed HM, Moody WE, Bradlow WM, et al. Echocardiographic findings in patients with COVID-19 pneumonia. Can J Cardiol. 2020;36(6):1203–1207.
9. Fox K, Prokup JA, Butson K, Jordan K. Acute effusive pericarditis: a late complication of COVID-19. Cureus. 2020;12(7):e9074.
10. Zeng JH, Wu WB, Ou JX, et al. Cardiac manifestations of COVID-19 in Shenzhen, China. Infection. 2020;48(6):861–870.